8-K: Pfizer Revises 2025 Revenue, Sets 2026 Guidance

Pfizer Inc. revised its full-year 2025 revenue guidance downwards while reaffirming EPS and providing full-year 2026 financial projections.

Summary

• Full-year 2025 Revenue guidance was revised to approximately $62.0 billion, down from the previously stated range of $61.0 to $64.0 billion.
• Full-year 2025 Adjusted Diluted EPS guidance was reaffirmed in the range of $3.00 to $3.15.
• Full-year 2026 Revenue guidance is anticipated to be in the range of $59.5 to $62.5 billion.
• Full-year 2026 Adjusted Diluted EPS guidance is projected to be in the range of $2.80 to $3.00.
• The 2026 revenue guidance includes an expected approximately $1.5 billion lower revenue from COVID-19 products compared to 2025.
• An additional negative revenue impact of approximately $1.5 billion is expected in 2026 due to certain products experiencing loss of exclusivity (LOE).
• Full-year 2026 operational revenue growth, excluding both COVID-19 and LOE products, is expected to be approximately 4% year-over-year at the midpoint.
• Full-year 2026 Adjusted Selling, Information & Administrative (SI&A) expenses are anticipated to be $12.5 to $13.5 billion, reflecting progress with the Cost Realignment Program.
• Full-year 2026 Adjusted Research & Development (R&D) expenses are anticipated to be $10.5 to $11.5 billion, focusing on key therapeutic areas and development of PF-08634404 and Metsera programs.
• Total 2026 Adjusted SI&A and R&D expenses are expected to be in the range of $23.0 to $25.0 billion.
• The anticipated effective tax rate on Adjusted income for 2026 is approximately 15%, higher than the approximately 11% for 2025.

Sentiment

Score: 4

Explanation: While 2025 EPS was reaffirmed and there's operational growth ex-COVID/LOE, the downward revision of 2025 revenue and lower 2026 revenue and EPS guidance, driven by significant headwinds from COVID-19 product decline and LOE, indicates a challenging near-term outlook. The increased tax rate also contributes to the lower EPS.

Positives

• Reaffirmed full-year 2025 Adjusted Diluted EPS guidance of $3.00 to $3.15.
• Expected full-year 2026 operational revenue growth of approximately 4% year-over-year, excluding COVID-19 and LOE products, indicating underlying business strength.
• Ongoing progress with the Cost Realignment Program is expected to lead to lower Adjusted SI&A expenses in 2026 ($12.5 $13.5 billion) compared to 2025 ($13.1 $14.1 billion).
• Continued investment in the R&D pipeline and acquired assets (PF-08634404, Metsera programs) is planned to fuel long-term growth.

Negatives

• Full-year 2025 Revenue guidance was revised downwards to approximately $62.0 billion from the previous range of $61.0 to $64.0 billion.
• Full-year 2026 Revenue guidance of $59.5 to $62.5 billion is lower than the revised 2025 guidance.
• Full-year 2026 Adjusted Diluted EPS guidance of $2.80 to $3.00 is lower than the reaffirmed 2025 guidance of $3.00 to $3.15.
• Expected approximately $1.5 billion lower revenue from COVID-19 products in 2026 compared to 2025.
• Anticipated negative revenue impact of approximately $1.5 billion in 2026 due to loss of exclusivity (LOE) for certain products.
• Anticipated higher effective tax rate on Adjusted income for 2026 (approximately 15%) compared to 2025 (approximately 11%).

Risks

• The outcome of research and development (R&D) activities, including the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for trials, regulatory submission dates, and/or regulatory approval and/or launch dates.
• The possibility of unfavorable pre-clinical and clinical trial results, including new data and further analyses of existing data, and risks associated with preliminary, early stage or interim data.
• The risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments by the scientific community and regulatory authorities.
• Uncertainties regarding the future development of product candidates, including whether or when they will advance to future studies or phases of development or whether or when regulatory applications may be filed.
• The ability to successfully address comments received from regulatory authorities (e.g., U.S. Food and Drug Administration or European Medicines Agency) or obtain approval for new products and indications on a timely basis or at all.
• Regulatory decisions impacting labeling, approval or authorization, including the scope of indicated patient populations, product dosage, manufacturing processes, safety and/or other matters, including decisions relating to emerging developments regarding potential product impurities.
• Uncertainties regarding the ability to obtain or maintain, and the scope of, recommendations by technical or advisory committees, and the timing of, and ability to obtain, pricing approvals and product launches.
• Claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including from post-approval clinical trials, pharmacovigilance or Risk Evaluation and Mitigation Strategies.
• The success and impact of external business development activities, such as the November 2025 acquisition of Metsera, including the ability to identify and execute on potential opportunities.
• The ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all, and the ability to realize the anticipated benefits of any such transactions.
• The potential need for and impact of additional equity or debt financing to pursue business development opportunities, which could result in increased leverage and/or a downgrade of credit ratings.
• Challenges integrating acquired businesses and operations, disruption to business or operations relationships, risks related to growing revenues for certain acquired or partnered products, significant transaction costs, and unknown liabilities.
• Competition, including from new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates.
• The ability to successfully market both new and existing products, including biosimilars.
• Difficulties or delays in manufacturing, sales or marketing; supply disruptions, shortages or stock-outs at facilities or third-party facilities.
• Legal or regulatory actions.
• The impact of public health outbreaks, epidemics or pandemics (such as COVID-19) on business, operations and financial condition and results.
• Risks and uncertainties related to Comirnaty and Paxlovid or any potential future COVID-19 vaccines, treatments or combinations, including reduced demand, excess inventory, or unanticipated charges if the market remains endemic/seasonal or infection rates do not follow prior patterns.
• Risks related to the ability to develop, receive regulatory approval for, and commercialize variant adapted vaccines, combinations and/or treatments.
• Uncertainties related to recommendations and coverage for, and the public's adherence to, vaccines, boosters, treatments or combinations, including the potential impact of narrowing recommended patient populations.
• Whether or when EUAs or biologics licenses will expire, terminate or be revoked, and risks related to the ability to accurately predict or achieve revenue forecasts for COVID-19 products.
• Potential third-party royalties or other claims related to Comirnaty and Paxlovid.
• Trends toward managed care and healthcare cost containment, and the ability to obtain or maintain timely or adequate pricing or favorable formulary placement for products.
• Interest rate and foreign currency exchange rate fluctuations, including the impact of global trade tensions, currency devaluations and monetary policy actions in countries experiencing high inflation or deflation rates.
• Any significant issues involving largest wholesale distributors or government customers, which account for a substantial portion of revenues.
• The impact of the increased presence of counterfeit medicines, vaccines or other products in the pharmaceutical supply chain.
• Any significant issues related to the outsourcing of certain operational and staff functions to third parties.
• Any significant issues related to joint ventures (JVs) and other third-party business arrangements, including modifications or disputes related to supply agreements or other contracts.
• Uncertainties related to general economic, political, business, industry, regulatory and market conditions, including challenging global economic conditions (e.g., inflation, interest rate fluctuations) and recent and possible future changes in global financial markets.
• The exposure of global operations to possible capital and exchange controls, economic conditions, expropriation, sanctions, tariffs and/or other restrictive government actions, changes in intellectual property legal protections and remedies, unstable governments and legal systems and inter-governmental disputes.
• Risks and uncertainties related to issued or future executive orders or other new, or changes in, laws, regulations or policy regarding tariffs or other trade policy and/or the impact of any potential U.S. Governmental shutdowns.
• The risk and impact of tariffs on the business, which is subject to a number of factors including, but not limited to, restrictions on trade, effective date and duration of tariffs, countries included in scope of tariffs, changes to amounts of tariffs, and potential retaliatory tariffs or other retaliatory actions.
• The impact of disruptions related to climate change and natural disasters.
• Any changes in business, political and economic conditions due to actual or threatened terrorist activity, geopolitical instability, political or civil unrest or military action, including the ongoing conflicts between Russia and Ukraine and in the Middle East.
• The impact of product recalls, withdrawals and other unusual items, including uncertainties related to regulator-directed risk evaluations and assessments (e.g., nitrosamines) and the voluntary withdrawal of all lots of Oxbryta.
• Trade buying patterns.
• The risk of an impairment charge related to intangible assets, goodwill or equity-method investments.
• The impact of, and risks and uncertainties related to restructurings and internal reorganizations, corporate strategic initiatives and growth strategies, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs, organizational disruption, adverse effects on employee morale, retention issues or other unintended consequences.
• The ability to successfully achieve climate-related goals and progress environmental sustainability and other priorities.
• The impact of any U.S. healthcare reform or legislation, including executive orders or other change in laws, regulations or policy, or any significant spending reduction or cost control efforts affecting Medicare, Medicaid, the 340B Drug Pricing Program or other publicly funded or subsidized health programs, including the Inflation Reduction Act of 2022 (IRA) and the IRA Medicare Part D Redesign.
• Risks and uncertainties related to the impact of Pfizer's voluntary agreement with the U.S. Government designed to lower drug costs for U.S. patients and to include Pfizer products in a direct purchasing platform, and Pfizer's plans to further invest in U.S. manufacturing.
• U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property, reimbursement or access to or recommendations for medicines and vaccines, tax changes or other restrictions on U.S. direct-to-consumer advertising; limitations on interactions with healthcare professionals and other industry stakeholders; as well as pricing pressures for products as a result of highly competitive biopharmaceutical markets.
• Risks and uncertainties related to changes to vaccine or other healthcare policy in the U.S., including the U.S. Food and Drug Administration's recently adopted policy of disclosing Complete Response Letters for unapproved drug candidates.
• Legislation or regulatory action in markets outside of the U.S., such as China or Europe, including, without limitation, laws related to pharmaceutical product pricing, intellectual property, medical regulation, environmental protections, data protection and cybersecurity, reimbursement or access.
• Legal defense costs, insurance expenses, settlement costs and contingencies, including without limitation, those related to legal proceedings and actual or alleged environmental contamination.
• The risk and impact of an adverse decision or settlement and risk related to the adequacy of reserves related to legal proceedings.
• The risk and impact of tax related litigation and investigations.
• Governmental laws, regulations and policies affecting operations, including, without limitation, the IRA, as well as changes in such laws, regulations or policies or their interpretation, including, among others, new or changes in tariffs, tax laws and regulations internationally and in the U.S. (e.g., the One Big Beautiful Bill Act enacted on July 4, 2025), the adoption of global minimum taxation requirements, government cost-cutting measures, restrictions related to certain data transfers and transactions involving certain countries, and potential changes to existing tax laws, tariffs, or other laws, regulations or policies.
• The risk that currently pending or future patent applications may not be granted on a timely basis or at all, or any patent-term extensions sought may not be granted.
• Risks to products, patents and other intellectual property, such as claims of invalidity, claims of patent infringement, claims asserted against third-party intellectual property rights, challenges faced by collaboration or licensing partners to the validity of their patent rights, or pressure from stakeholders or governments that could potentially result in not seeking intellectual property protection or agreeing not to enforce or being restricted from enforcing intellectual property rights.
• Any significant breakdown or interruption of information technology systems and infrastructure (including cloud services).
• Any business disruption, theft of confidential or proprietary information, security threats on facilities or infrastructure, extortion or integrity compromise resulting from a cyber-attack (which may include those using adversarial artificial intelligence techniques) or other malfeasance.
• Risks and challenges related to the use of software and services that include artificial intelligence-based functionality and other emerging technologies.

Future Outlook

Pfizer anticipates full-year 2026 revenues to be between $59.5 and $62.5 billion, with Adjusted Diluted EPS in the range of $2.80 to $3.00. This outlook reflects a significant impact from lower COVID-19 product revenues and loss of exclusivity, partially offset by an expected 4% operational revenue growth (excluding these factors) and ongoing cost realignment efforts. The company plans continued investment in its pipeline and acquired assets to fuel long-term growth and position itself for sustainable growth in the post-LOE period.

Management Comments

• "2025 was a year of strong execution and strategic progress for Pfizer."
• "We've strengthened our foundation, advanced our R&D pipeline and positioned our company for sustainable growth in the post-LOE period."
• "As we move into 2026, we're focused on serving patients with innovative medicines and vaccines while creating long-term value for our shareholders."

Industry Context

The pharmaceutical industry faces ongoing challenges from patent expirations (loss of exclusivity or LOE) and evolving demand for COVID-19 related products. Pfizer's guidance reflects these trends, with significant revenue headwinds from both LOE and declining COVID-19 product sales. The company's strategy to offset these impacts through cost realignment and continued investment in its R&D pipeline, including recent acquisitions like Metsera and licensing agreements like 3SBio, is a common approach in the industry to drive future growth amidst these pressures. The anticipated operational revenue growth (excluding COVID-19 and LOE) suggests underlying strength in its core business, indicating a strategic pivot towards its non-COVID portfolio.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess Pfizer's performance against global benchmarks. The guidance is presented in the context of internal company performance and strategic initiatives.

Legal Proceedings

• The filing mentions general risks related to legal defense costs, insurance expenses, settlement costs and contingencies, including those related to legal proceedings and actual or alleged environmental contamination.
• It also notes risks and impact of an adverse decision or settlement and adequacy of reserves related to legal proceedings, and tax-related litigation and investigations.
• No specific new legal proceedings are disclosed in this filing.

Stakeholder Impact

• Shareholders: Potential for reduced near-term returns due to lower revenue and EPS guidance, but the company aims for long-term value creation through pipeline investment and cost realignment.
• Employees: The Cost Realignment Program, while aimed at efficiency, could imply workforce adjustments, though specific details are not provided.
• Customers/Patients: Continued focus on serving patients with innovative medicines and vaccines. Risks related to product safety/efficacy claims and regulatory decisions could impact patient access.
• Suppliers/Partners: Risks related to supply disruptions and issues with joint ventures and other third-party business arrangements are noted.
• Creditors: Potential for increased leverage and/or credit rating downgrade if additional debt financing is pursued for business development activities.

Next Steps

• Pfizer will host a live conference call and webcast on December 16, 2025, at 8:00 AM EST to discuss the guidance.
• A transcript and webcast replay of the call will be made available on pfizer.com/investors within 24 hours after the end of the live conference call and will be accessible for at least 90 days.

Key Dates

Recommendation

The revised 2025 revenue guidance and the lower 2026 revenue and EPS projections, primarily due to expected declines in COVID-19 product sales and significant loss of exclusivity impacts, present near-term headwinds. While the company is investing in its pipeline and implementing cost realignment, these efforts are aimed at long-term growth and do not fully offset the immediate challenges. The operational growth excluding COVID-19 and LOE is positive, but the overall financial outlook suggests a period of transition. An investor would likely hold to observe the effectiveness of pipeline investments and cost-saving measures in stabilizing and growing revenues beyond the immediate LOE and COVID-19 impacts.

Keywords

Pfizer, PFE, pharmaceutical, financial guidance, revenue, EPS, 2025, 2026, COVID-19 products, loss of exclusivity, LOE, R&D expenses, SI&A expenses, pipeline investment, Metsera, 3SBio, cost realignment, tax rate